RESUMO
Although there have been extensive anatomical and physiological studies in animals, the actual neural sources, or even the laterality, of some components of auditory brain-stem evoked potentials in humans are uncertain. We studied these responses in a 56-year-old patient who had a clearly demarcated pontine hemorrhage on the right side. The patient was somnolent, with dense left hemiplegia and signs of involvement of right cranial nerves V, VI, and VII. Stimulation of the left ear (ie, contralateral to the lesion) evoked a normal series of waves with clearly resolved positive components peaking at 2.0, 3.3, 4.8 (wave IV), and 6.0 ms (wave V). Stimulation of the right ear (ie, ipsilateral to the lesion) evoked only waves I, III, and IV. These results suggest that a pathway ipsilateral to the stimulated ear is necessary and sufficient for generation of auditory wave V and that wave IV is generated in bilateral pathways.
Assuntos
Hemorragia Cerebral/fisiopatologia , Potenciais Evocados Auditivos , Ponte/fisiopatologia , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Induced pecking by apomorphine has been reported in the past in pigeons. Research has supported the view that its mechanisms are, at least in part, dopaminergic in nature. This study tested the ability of amphetamine to induce stereotyped pecking. Amphetamine was found effective within a narrow dose range, displaying a relatively low potency for stereotyped pecking and high toxicity compared with apomorphine. The latter drug produced appreciable pecking rates that were proportional to dose over a wide range. The description of other stereotyped responses of the head and mouth, including swallowing, mandibulating and head shaking, which are produced by both of these drugs, supports the idea that common neural mechanisms are involved. It was suggested that the qualitative and quantitative measures afforded by pecking and non-pecking stereotyped behavior in the pigeon make this a useful animal model for the study of the mechanisms of stereotyped behavior.
Assuntos
Anfetamina/farmacologia , Apomorfina/farmacologia , Comportamento Estereotipado/efeitos dos fármacos , Animais , Columbidae , Relação Dose-Resposta a Droga , Humanos , PosturaRESUMO
There is growing evidence for a role of extrahypothalamic corticotropin-releasing factor (CRF) in the pathogenesis of anxiety. A modified form of the defensive withdrawal test was used to test the anxiogenic effects of acute administration of intracerebroventricular (1 microg, i.c.v.) CRF in adult male rats. Habituation to the mild stress of daily handling and subcutaneous (s.c.) saline injection over 2-6 weeks abolished the anxiogenic effects of exogenous CRF. At 6 weeks this habituation also resulted in attenuation of baseline withdrawal behavior. CRF receptor binding was significantly decreased in the amygdala of chronically handled animals and may have been responsible for this habituation phenomenon. Comparison of rats treated with the monoamine oxidase (MAO) inhibitor, phenelzine [3 mg/kg, s.c., daily for 2-6 weeks] to the saline-treated groups revealed a failure to habituate to the chronic handling, as the baseline withdrawal (after injection of artificial CSF) by the phenelzine-treated animals was not different from the baseline withdrawal by unhandled rats. In comparison to rats treated chronically with saline, phenelzine treatment enhanced the anxiogenic effect of CRF. In summary, habituation to a mild chronic stress decreased baseline defensive withdrawal. Intraventricular administration of CRF produced an anxiogenic response as measured in the defensive withdrawal test, which was lost through exposure to mild chronic stress. Two or 6 weeks of daily handling and SC saline injection caused a downregulation of CRF receptors in the amygdala, which could account for the behavioral habituation and the loss of CRF-induced defensive withdrawal. Phenelzine treatment concurrent with mild chronic stress prevented habituation and maintained the anxiogenic effect of CRF in spite of the downregulation of CRF receptors in the amygdala.